Entellus Medical Inc. (NASDAQ:ENTL) traded up 3.8% on Tuesday . The stock traded as high as $20.27 and last traded at $19.98, with a volume of 56,263 shares. The stock had previously closed at $19.24.

ENTL has been the subject of a number of recent analyst reports. BTIG Research restated a “buy” rating on shares of Entellus Medical in a research report on Wednesday, June 29th. Zacks Investment Research upgraded shares of Entellus Medical from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research report on Monday, August 8th. Canaccord Genuity restated a “buy” rating and issued a $23.00 price objective on shares of Entellus Medical in a research report on Friday, August 5th. Finally, Bank of America Corp. restated a “buy” rating on shares of Entellus Medical in a research report on Monday, July 18th. Six analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average target price of $23.00.

The company’s market capitalization is $376.41 million. The stock’s 50-day moving average price is $18.73 and its 200 day moving average price is $17.61.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/entellus-medical-inc-entl-trading-3-8-higher.html

Entellus Medical (NASDAQ:ENTL) last released its earnings results on Wednesday, August 3rd. The medical technology company reported ($0.27) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.35) by $0.08. The company earned $18.73 million during the quarter, compared to the consensus estimate of $18.48 million. Entellus Medical had a negative net margin of 33.54% and a negative return on equity of 41.83%. The company’s revenue was up 23.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.15) EPS. Equities analysts anticipate that Entellus Medical Inc. will post ($1.23) EPS for the current year.

In other news, VP Timothy B. Petrick sold 3,000 shares of the business’s stock in a transaction dated Monday, July 18th. The shares were sold at an average price of $18.15, for a total value of $54,450.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP James D. Surek sold 10,000 shares of the business’s stock in a transaction dated Thursday, September 8th. The stock was sold at an average price of $18.71, for a total transaction of $187,100.00. Following the completion of the sale, the vice president now directly owns 95,031 shares of the company’s stock, valued at approximately $1,778,030.01. The disclosure for this sale can be found here. 9.10% of the stock is currently owned by insiders.

Several large investors have recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. increased its stake in shares of Entellus Medical by 1.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 17,025 shares of the medical technology company’s stock worth $312,000 after buying an additional 210 shares in the last quarter. Grandeur Peak Global Advisors LLC increased its stake in shares of Entellus Medical by 218.1% in the second quarter. Grandeur Peak Global Advisors LLC now owns 21,950 shares of the medical technology company’s stock worth $401,000 after buying an additional 15,050 shares in the last quarter. Murphy Michael R increased its stake in shares of Entellus Medical by 30.1% in the second quarter. Murphy Michael R now owns 627,441 shares of the medical technology company’s stock worth $11,463,000 after buying an additional 145,304 shares in the last quarter. Ghost Tree Capital LLC increased its stake in shares of Entellus Medical by 9.1% in the second quarter. Ghost Tree Capital LLC now owns 120,000 shares of the medical technology company’s stock worth $2,192,000 after buying an additional 10,000 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Entellus Medical by 89.2% in the second quarter. State Street Corp now owns 96,040 shares of the medical technology company’s stock worth $1,753,000 after buying an additional 45,267 shares in the last quarter. 66.22% of the stock is owned by institutional investors.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear, nose and throat (ENT) physicians to treat patients with symptomatic inflammation of the nasal sinuses by opening narrowed or obstructed sinus drainage pathways using balloon sinus dilation.

5 Day Chart for NASDAQ:ENTL

Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.